PL2234595T3 - Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania - Google Patents

Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania

Info

Publication number
PL2234595T3
PL2234595T3 PL08859423T PL08859423T PL2234595T3 PL 2234595 T3 PL2234595 T3 PL 2234595T3 PL 08859423 T PL08859423 T PL 08859423T PL 08859423 T PL08859423 T PL 08859423T PL 2234595 T3 PL2234595 T3 PL 2234595T3
Authority
PL
Poland
Prior art keywords
glycopyyronium
aggegate
tendency
salt
reducing
Prior art date
Application number
PL08859423T
Other languages
English (en)
Inventor
Gerhard Muhrer
Norbert Rasenack
Michael Juhnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39472711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2234595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2234595T3 publication Critical patent/PL2234595T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08859423T 2007-12-13 2008-12-11 Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania PL2234595T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123164 2007-12-13
EP08859423A EP2234595B1 (en) 2007-12-13 2008-12-11 Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
PCT/EP2008/067359 WO2009074662A2 (en) 2007-12-13 2008-12-11 Organic compounds

Publications (1)

Publication Number Publication Date
PL2234595T3 true PL2234595T3 (pl) 2013-04-30

Family

ID=39472711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08859423T PL2234595T3 (pl) 2007-12-13 2008-12-11 Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania

Country Status (13)

Country Link
US (1) US20100247658A1 (pl)
EP (1) EP2234595B1 (pl)
JP (1) JP2011506399A (pl)
KR (1) KR20100099281A (pl)
CN (1) CN101896162B (pl)
AU (1) AU2008334543B2 (pl)
BR (1) BRPI0821186A2 (pl)
CA (1) CA2708083C (pl)
ES (1) ES2396471T3 (pl)
PL (1) PL2234595T3 (pl)
PT (1) PT2234595E (pl)
RU (1) RU2482838C2 (pl)
WO (1) WO2009074662A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
PL3490533T3 (pl) * 2016-07-29 2020-11-02 Inke, S.A. Sposób stabilizacji rozmiaru cząstek
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
IT202300022716A1 (it) * 2023-10-30 2025-04-30 Ind Chimica Srl Processo di condizionamento di fluticasone furoato micronizzato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ES2587135T3 (es) * 2000-11-30 2016-10-20 Vectura Limited Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
WO2005046655A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
BRPI0509184A (pt) * 2004-03-23 2007-09-18 Novartis Ag composições farmacêuticas
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006073154A1 (ja) * 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. 医薬組成物及びその製造方法
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
KR20100099281A (ko) 2010-09-10
ES2396471T3 (es) 2013-02-21
WO2009074662A2 (en) 2009-06-18
WO2009074662A3 (en) 2009-09-24
CN101896162B (zh) 2013-06-05
EP2234595B1 (en) 2012-11-28
CN101896162A (zh) 2010-11-24
PT2234595E (pt) 2013-01-24
CA2708083A1 (en) 2009-06-18
RU2010128246A (ru) 2012-01-20
JP2011506399A (ja) 2011-03-03
AU2008334543B2 (en) 2011-07-28
AU2008334543A1 (en) 2009-06-18
EP2234595A2 (en) 2010-10-06
BRPI0821186A2 (pt) 2015-06-16
US20100247658A1 (en) 2010-09-30
CA2708083C (en) 2016-06-28
RU2482838C2 (ru) 2013-05-27

Similar Documents

Publication Publication Date Title
PT2234595E (pt) Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
AP2577A (en) Process for preparing diaminophenothiazinium compounds
ZA201104425B (en) A method for the production of pellets or briquettes
TWI371277B (en) Salt form
ZA201401797B (en) Fungicidal substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl ]-2-alkoxy-2-cyclyl-ethyl}-1h [1,2,4]triazole compounds
IL199124A (en) A process for preparing fluoromethyl-converted heterocyclic compounds
IL206390A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
ZA201200890B (en) 5,6-bicylic heteroaryl-containing urea compounds as kinase inhibitors
IL207408A0 (en) Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates
IL212639A0 (en) Piperazine salt and a process for the preparation thereof
IL201670A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
GB0811007D0 (en) Process for makign crystals
ZA201003678B (en) Methods for salt production
PL2143429T3 (pl) Zastosowanie cylastatyny do zmniejszania nefrotoksyczności różnych związków
PL2417086T3 (pl) Sposób wytwarzania 3,3,3-trifluoropropenu
GB0702382D0 (en) New salt
EP2289875A4 (en) PROCESS FOR PRODUCING PERFLUOROALCANESULFINIC ACID SALT
IL214110A0 (en) 2,3-diaryl-or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
EP2016066A4 (en) PROCESS FOR PREPARING DULOXETINE
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
IL209462A0 (en) Opiorphin for use as a psychotimulant agent
GB0719218D0 (en) Process tank
IL207190A0 (en) A process for the ultrapurification of alginates
ZA200907695B (en) Process for preparing dorzolam ide
IL213762A0 (en) 1,1,1-trifluoro-2-hydroxypropyl compounds